November 7, 2024 12:02 PM ESTUpdated 02:43 PM

FDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacy

Zachary Brennan

Senior Editor

After 17 years of back and forth with citizen petitions and two advisory committees, the FDA on Thursday proposed to pull commonly-used nasal decongestant active …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacy

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Pfizer to invest $1B in China over next five years — reports

Senior AstraZeneca exec detained in China amid wider investigation

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Avid Bioservices to be sold to private equity firms for $1.1B

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

FDA seeks to pull OTC nasal de­con­ges­tant in­gre­di­ent due to lack of ef­fi­ca­cy

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

FDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacy

Pfizer to invest $1B in China over next five years — reports

Senior AstraZeneca exec detained in China amid wider investigation

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Avid Bioservices to be sold to private equity firms for $1.1B

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks